Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02412982 · ClinicalTrials.gov registry record · Phase 4
Evaluation of Venous Thromboembolism Prevention in High-Risk Trauma Patients
A Phase 4 study, sponsored by University of Cincinnati.
- Completed
- Registry status
- Phase 4
- Development phase
- 103
- Enrollment target
NCT02412982 is a Phase 4 study that has completed, run by University of Cincinnati. The registered enrollment target is 103 participants.
The verdict
NCT02412982, a Phase 4 study, has completed, sponsored by University of Cincinnati.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 103 participants
- Enrollment target
Study Summary
This is a pilot study to determine if anti-thrombin III (AT-III) serum concentrations differ between patients with normal versus subtherapeutic anti-Xa trough concentrations when placed on enoxaparin 30 mg twice daily for VTE prophylaxis. Secondarily, this study will compare two enoxaparin dosing strategies.
Interventions
- DRUG Enoxaparin 40 mg q12h
- DRUG Enoxaparin 30 mg q8h
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2016-03 |
| Est. Completion | 2019-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02412982
The ClinicalTrials.gov registry entry for NCT02412982 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Cincinnati, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Enoxaparin 40 mg q12h is the first listed.
NCT02412982 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02412982 about?
NCT02412982 is a clinical study titled "Evaluation of Venous Thromboembolism Prevention in High-Risk Trauma Patients". This is a pilot study to determine if anti-thrombin III (AT-III) serum concentrations differ between patients with normal versus subtherapeutic anti-Xa trough concentrations when placed on enoxaparin 30 mg twice daily for VTE prophylaxis. Secondarily, this study will compare two enoxaparin dosing st...
What is the current status of trial NCT02412982?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 103 participants. The study started on 2016-03. Estimated completion is 2019-01.
What interventions are being tested in trial NCT02412982?
The interventions under investigation include: Enoxaparin 40 mg q12h (DRUG), Enoxaparin 30 mg q8h (DRUG).
Who is sponsoring clinical trial NCT02412982?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.